How the Late Stage Chronic Kidney Disease Drugs Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Primary Drivers Are Supporting the Continued Market Growth of theLate Stage Chronic Kidney Disease Drugs Market?
The escalating rate of chronic kidney diseases is anticipated to accelerate the expansion of the late-stage chronic kidney disease drug market. Chronic kidney diseases encompass a variety of conditions impacting the kidneys’ structure and functionality. Drugs intended for late-stage chronic kidney disease are utilized to regulate blood pressure, reduce protein loss which halts kidney deterioration, manage symptoms, and prevent adverse outcomes. For instance, the Centers for Disease Control and Prevention (CDC), a public health agency based in the US, estimated in May 2024 that about 14% or approximately 35.5 million of U.S. adults are presumed to be afflicted with chronic kidney diseases. Consequently, the high occurrence of chronic kidney disease is fostering the growth of the late-stage chronic kidney disease drug market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
#What is the Projected CAGR for the Late Stage Chronic Kidney Disease Drugs Market Size from 2025 to 2034?
In recent years, the market size for drugs targeting late stage chronic kidney disease has seen rapid expansion. Growth is predicted to continue, increasing from $7.08 billion in 2024 to $7.92 billion in 2025, at a compound annual growth rate (CAGR) of 11.9%. Numerous factors contributed to this historic period of growth, including enhanced diagnostic capabilities, an aging population, a rise in diabetes and hypertension, heightened awareness of kidney diseases, and the expansion of research and development within the pharmaceutical industry.
In the coming years, the market for late-stage chronic kidney disease drugs is expected to experience rapid expansion, increasing to a value of $12.2 billion by 2029. This represents a compound annual growth rate (CAGR) of 11.4%. This projected growth can be attributed to factors such as increased healthcare spending, the adoption of precision medicine, a focus on regenerative medicine, emphasis on patient-centric care, and global initiatives to create awareness on kidney disease. The future trend includes the expansion of regenerative medicine treatments, increased use of telemedicine services for managing CKD, the development of combination therapies, focus on early intervention strategies, and a growing interest in diagnostic methods based on biomarkers.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12196
How Are Consumer Market Innovations Shaping the Current and Future Landscape of theLate Stage Chronic Kidney Disease Drugs Market?
The rise of product innovation is a significant trend in the market for late-stage chronic kidney disease drugs. Leading companies in this market are formulating new drug products to maintain their market presence. For example, in February 2022, Bayer, a pharmaceutical and biotechnology firm based in Germany, introduced Kerendia (finerenone) to the Indian market. It is recommended for patients who have chronic renal disease and type two diabetes. Finerenone, a first-of-its-kind non-steroidal selective mineralocorticoid receptor antagonist, works by inhibiting the excess activation of the mineralocorticoid receptor (MR), which is believed to contribute to the progression of chronic kidney disease (CKD) and cardiovascular damage.
Who Are the Key Market Players Influencing the Growth of the Corn and Late Stage Chronic Kidney Disease Drugs Industry?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
Order Your Report Now For A Swift Delivery:
Which Key Market Segments Comprise the Late Stage Chronic Kidney Disease Drugs Market and Drive Its Revenue Growth?
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12196&type=smp
Which Regions Are Emerging as Leaders in the Late Stage Chronic Kidney Disease Drugs Market?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Gobal Late Stage Chronic Kidney Disease Drugs Maret 2025, By The Business Research Company:
Oil And Gas Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-and-gas-global-market-report
Oil Accumulator Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-accumulator-global-market-report
Oil And Gas Pumps Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-and-gas-pumps-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
